^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

aviscumine (CY-503)

i
Other names: CY-503, ME-503, BA503, mistletoe lectin recombinant, viscum ribosome inactivating protein
Associations
Trials
Company:
MELEMA Pharma
Drug class:
Ribosomal protein inhibitor
Associations
Trials
over1year
Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia. (PubMed, Bioengineered)
Plants are capable of the post-translational modifications needed for functional antibodies and can also express active protein toxins such as the recombinant mistletoe lectin viscumin, which is not possible in prokaryotes and mammalian cells respectively...One anti-CD64 targeted viscumin-based drug candidate was characterized in terms of storage stability and cytotoxicity test in vitro using human myelomonocytic leukemia cell lines. We identified bottlenecks in the plant-based expression platform that require further improvement and assessed critical process parameters that should be considered during process development for plant-made RITs.
Journal
|
aviscumine (CY-503)